Frequency of seronegativity in adult-acquired generalized myasthenia gravis

Muscle and Nerve

Volumn 36, Issue 5, 2007, Pages 651-658

  Koon, Ho Chan ^a   Lachance, Daniel H ^a   Harper, C Michel ^a   Lennon, Vanda A ^a  

^a MAYO CLINIC   (United States)

Author keywords

AChR antibody; Adult acquired myasthenia gravis; Autoantibody evaluation; MuSK antibody; Seronegative myasthenia gravis

Indexed keywords

ANTIBODY; AUTOANTIBODY; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; IMMUNOSUPPRESSIVE AGENT; MUSCLE SPECIFIC TYROSINE KINASE ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; CLINICAL FEATURE; ELECTROPHYSIOLOGY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MYASTHENIA GRAVIS; ONSET AGE; PRIORITY JOURNAL; RECEPTOR BINDING; SEROCONVERSION; SYMPTOMATOLOGY;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYASTHENIA GRAVIS; RADIOIMMUNOASSAY; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, CHOLINERGIC; RETROSPECTIVE STUDIES; SEROLOGY;

EID: 35448985820     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.20854     Document Type: Article

References (42)

1. Almon RR, Appel SH. Interaction of myasthenic serum globulin with the acetylcholine receptor. Biochim Biophys Acta 1975;393:66-77.
2. Andrews PI, Massey JM, Howard JF Jr, Sanders DB. Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis. Neurology 1994;44:1208-1214.
3. Beeson D, Amar M, Bermudez I, Vincent A, Newsom-Davis J. Stable functional expression of the adult subtype of human muscle acetylcholine receptor following transfection of the human rhabdomyosarcoma cell line TE671 with cDNA encoding the epsilon subunit. Neurosci Lett 1996;207:57-60.
4. Burges J, Vincent A, Molenaar PC, Newsom-Davis J, Peers C, Wray D. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 1994;17:1393-1400.
5. Cikes N, Momoi MY, Williams CL, Howard FM Jr, Hoagland HC, Whittingham S, et al. Striational autoantibodies: quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of D-penicillamine or allogeneic bone marrow. Mayo Clin Proc 1988;63:478-481.
6. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980;103:579-601.
7. Drachman DB, Angus CW, Adams RN, Michelson JD, Hoffman GJ. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N Engl J Med 1978;298:1116-1122.
8. Dyck PJ, Kratz KM, Lehman KA, Karnes JL, Melton LJ 3rd, O'Brien PC, et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991;41:799-807.
9. Dyck PJ, Litchy WJ, Lehman KA, Hokanson JL, Low PA, O'Brien PC. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. Neurology 1995;45:1115-1121.
10. Engel AG, Ohno K, Sine SM. Congenital myasthenic syndromes. In: Engel A, editor. Myasthenia gravis and myasthenic disorders. New York: Oxford University Press; 1999. p 251-297.
11. Evoli A, Tonali PA, Padua L, Monaco ML, Scuderi F, Batocchi AP, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304-2311.
12. Glass DJ, Bowen DC, Stitt TN, Radziejewski C, Bruno J, Ryan TE, et al. Agrin acts via a MuSK receptor complex. Cell 1996;85:513-523.
13. Griesmann GE, Harper CM, Lennon VA. Paraneoplastic myasthenia gravis and lung carcinoma: distinction from Lambert-Eaton syndrome and hypothesis of aberrant muscle acetylcholine receptor (ACmR) expression. Muscle Nerve 1998;7:S122.
14. Griesmann GE, Kryzer TJ, Lennon VA. Autoantibody profiles of myasthenia gravis and Lambert-Eaton myasthenic syndrome. In: Rose NR, Hamilton RG, Detrick B, editors. Manual of clinical and laboratory immunology, 6th ed. Washington, DC: ASM Press; 2002. p 1005-1012.
15. Grob D, Simpson D, Mitsumoto H, Hoch B, Mokhtarian F, Bender A, et al. Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 1995;45:338-344.
16. Harper CM, Lennon VA. Lambert-Eaton Syndrome. In: Kaminski HJ, editor. Current clinical neurology: myasthenia gravis and related disorders. Totowa, NJ: Humana Press; 2007.
17. Hoch W, McConville J, Helms S, Newsom-Dayis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-368.
18. Howard FM Jr, Lennon VA, Finley J, Matsumoto J, Elveback LR. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci 1987;505:526-538.
19. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
20. Keesey JC. Clinical evaluation and management of myasthenia gravis. Muscle Nerve 2004;29:484-505.
21. Lauriola L, Ranelletti F, Maggiano N, Guerriero M, Punzi C, Marsili F, et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005;64:536-538.
22. Lavrnic D, Losen M, Vujic A, De Baets M, Hajdukovic LJ, Stojanovic V, et al. The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry 2005;76:1099-1102.
23. Lefvert AK, Bergstrom K, Matell G, Osterman PO, Pirskanen R. Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications. J Neurol Neurosurg Psychiatry 1978;41:394-403.
24. Lennon VA. Serological diagnosis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome. In: Lisak R, editor. Handbook of myasthenia gravis and myasthenic syndromes. New York: Marcel Dekker; 1994. p 149-164.
25. Lennon VA. Serological profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome. Neurology 1997;48:S23-S27.
26. Lennon VA, Howard FM Jr. Serologic diagnosis of myasthenia gravis. In: Nakamura R, editor. Clinical laboratory molecular analyses. Orlando, FL: Grune & Straton; 1985. p 29-44.
27. Lennon VA, Kryzer TJ, Griesmann GE, O'Sulleabhain PE, Windebank AJ, Woppmann A, et al. Calcium-channel antibodies in Lambert-Eaton myasthenic syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467-1474.
28. Lennon VA, Lambert EH, Whittingham S, Fairbanks V. Autoimmunity in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1982;5:S21-25.
29. Limburg PC, The TH, Hummel-Tappel E, Oosterhuis HJ. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients. J Neurol Sci 1983;58:357-370.
30. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duanc DD. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. 1975. Neurology 1998;51:933-939.
31. McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 2004;55:580-584.
32. McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989;321:1567-1571.
33. Miller RG, Milner-Brown HS, Dau PC. Antibody-negative acquired myasthenia gravis: successful therapy with plasma exchange. Muscle Nerve 1981;4:255.
34. Mossman S, Vincent A, Newsom-Davis J. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. Lancet 1986;1:116-119.
35. Sanders DB, Andrews PI, Howard JF, et al. Seronegative myasthenia gravis. Neurology 1997;48:S40-S45.
36. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology 2003;60:1978-1980.
37. Sanders DB, Howard JF, Massey JM, Mihovilovic M, Olanow CW, Roses AD, et al. Seronegative myasthenia gravis. Ann Neurol 1987;22(Suppl):P27.
38. Scuderi F, Marino M, Colonna L, Mannella F, Evoli A, Provenzano C, et al. Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab Invest 2002;82:1139-1146.
39. Soliven BC, Lange DJ, Penn AS, Younger D, Jaretzki A 3rd, Lovelace RE, et al. Seronegative myasthenia gravis. Neurology 1988;38:514-517.
40. Tindall RS. Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations. Ann Neurol 1981;10:437-447.
41. Vernino S, Lennon VA. Autoantibody profiles and neurological correlations of thymoma. Clin Can Res 2004;10:7270-7275.
42. Vincent A, McConville J, Farrugia ME, Newsom-Davis J. Seronegative myasthenia gravis. Semin Neurol 2004;24:125-133.